OTCPK:LMTC.F

Stock Analysis Report

Executive Summary

Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.

Risks

  • Sona Nanotech is not covered by any analysts.

Share Price & News

How has Sona Nanotech's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:LMTC.F

-0.9%

US Medical Equipment

1.3%

US Market


1 Year Return

n/a

OTCPK:LMTC.F

9.1%

US Medical Equipment

2.0%

US Market

No trading data on LMTC.F.

No trading data on LMTC.F.


Share holder returns

LMTC.FIndustryMarket
7 Day0%-0.9%1.3%
30 Day13.5%0.7%3.9%
90 Day-14.2%4.4%3.4%
1 Yearn/a10.0%9.1%4.2%2.0%
3 Yearn/a70.7%65.5%47.2%37.6%
5 Yearn/a130.7%104.3%60.5%42.9%

Price Volatility Vs. Market

How volatile is Sona Nanotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sona Nanotech undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Sona Nanotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sona Nanotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of LMTC.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sona Nanotech regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Sona Nanotech expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sona Nanotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of LMTC.F’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Sona Nanotech's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Sona Nanotech performed over the past 5 years?

-632.6%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Sona Nanotech does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare Sona Nanotech's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Sona Nanotech's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Sona Nanotech has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Sona Nanotech has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Sona Nanotech improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Sona Nanotech's financial position?


Financial Position Analysis

Sona Nanotech's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

Sona Nanotech's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Sona Nanotech has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Sona Nanotech's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Sona Nanotech has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Sona Nanotech has less than a year of cash runway based on current free cash flow.

Sona Nanotech has less than a year of cash runway if free cash flow continues to grow at historical rates of 69.2% each year.


Next Steps

Dividend

What is Sona Nanotech's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Sona Nanotech's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Sona Nanotech's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Sona Nanotech has not reported any payouts.

Unable to verify if Sona Nanotech's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Sona Nanotech has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Sona Nanotech's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Darren Rowles (39yo)

1.9yrs

Tenure

CA$153,171

Compensation

Mr. Darren Rowles has been President and Chief Executive Officer at Sona Nanotech Limited since October 2017. Mr. Rowles has almost 15 years of experience in the diagnostic and nanoparticle industry and pr ...


CEO Compensation Analysis

Darren's remuneration is lower than average for companies of similar size in United States of America.

Insufficient data for Darren to compare compensation growth.


Management Age and Tenure

3.8yrs

Average Tenure

The tenure for the Sona Nanotech management team is about average.


Board Age and Tenure

6.6yrs

Average Tenure

61yo

Average Age

The tenure for the Sona Nanotech board of directors is about average.


Insider Trading

More shares have been bought than sold by Sona Nanotech individual insiders in the past 3 months, but not in substantial volumes.


Recent Insider Transactions

BuyCA$70,39119 Jul 19
Numus Financial
EntityCompany
Shares367,200
Max PriceCA$0.19
BuyCA$205,65519 Jul 19
Brigus Capital Incorporated
EntityCompany
Shares1,072,812
Max PriceCA$0.19
BuyCA$23,00419 Jul 19
Robert William Randall
EntityIndividual
Role
Chief Financial Officer
CFO & Corporate Secretary
Shares120,000
Max PriceCA$0.19
BuyCA$1,00928 Mar 19
Birch Point Holdings, Inc.
EntityCompany
Shares5,000
Max PriceCA$0.20
BuyCA$4,19321 Mar 19
Birch Point Holdings, Inc.
EntityCompany
Shares20,000
Max PriceCA$0.21
BuyCA$16,88714 Mar 19
Birch Point Holdings, Inc.
EntityCompany
Shares75,000
Max PriceCA$0.23
BuyCA$1,14808 Feb 19
Birch Point Holdings, Inc.
EntityCompany
Shares5,000
Max PriceCA$0.23
BuyCA$5,64708 Feb 19
Daniel Whittaker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares25,000
Max PriceCA$0.23
SellCA$19,16714 Jan 19
Birch Point Holdings, Inc.
EntityCompany
Shares158,207
Max PriceCA$0.12
BuyCA$4,97201 Jan 19
Birch Point Holdings, Inc.
EntityCompany
Shares29,500
Max PriceCA$0.17
BuyCA$13,48401 Jan 19
Daniel Whittaker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares80,000
Max PriceCA$0.17
BuyCA$28,33228 Dec 18
Birch Point Holdings, Inc.
EntityCompany
Shares156,000
Max PriceCA$0.18
BuyCA$19,34012 Oct 18
Andrew Smith
EntityIndividual
Shares100,000
Max PriceCA$0.19
BuyCA$85,09611 Oct 18
Numus Financial
EntityCompany
Shares440,000
Max PriceCA$0.19
BuyCA$73,49211 Oct 18
Harold Megann
EntityIndividual
Shares380,000
Max PriceCA$0.19
BuyCA$58,02011 Oct 18
Robert McKay
EntityIndividual
Role
Member of the Board of Directors
Director
Shares300,000
Max PriceCA$0.19
BuyCA$38,68003 Oct 18
Daniel Whittaker
EntityIndividual
Role
Member of the Board of Directors
Director
Shares200,000
Max PriceCA$0.19

Ownership Breakdown


Management Team

  • Rob Randall (56yo)

    CFO & Corporate Secretary

    • Tenure: 1.8yrs
    • Compensation: CA$77.44k
  • Kulbir Singh

    CTO & Founder

    • Tenure: 5.7yrs
  • Mike McAlduff

    Director of R&D & Production and Founder

    • Tenure: 5.7yrs
  • Gerrard Marangoni

    Product Science Advisor & Founder

    • Tenure: 0yrs
  • Darren Rowles (39yo)

    President & CEO

    • Tenure: 1.9yrs
    • Compensation: CA$153.17k

Board Members

  • Dan Whittaker (61yo)

    Director

    • Tenure: 0yrs
  • Wade Dawe (49yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: CA$15.79k
  • Michael Gross

    Director

    • Tenure: 0.4yrs
  • Zeph Mbugua (69yo)

    Director

    • Tenure: 6.6yrs
    • Compensation: CA$14.09k
  • Robert McKay

    Director

    • Tenure: 6.7yrs
    • Compensation: CA$14.09k
  • Catherine Murphy

    Member of Advisory Board

    • Tenure: 0yrs
  • Shine Zhang

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Sona Nanotech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sona Nanotech Inc.
  • Ticker: LMTC.F
  • Exchange: OTCPK
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: CA$11.537m
  • Listing Market Cap: CA$8.699m
  • Shares outstanding: 53.66m
  • Website: https://www.sonanano.com

Location

  • Sona Nanotech Inc.
  • Purdy’s Wharf Tower II
  • Suite 2001
  • Halifax
  • Nova Scotia
  • B3J 3R7
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SONACNSX (Canadian National Stock Exchange)YesCommon SharesCACADOct 2018
LMTC.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDOct 2018

Biography

Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800N ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:51
End of Day Share Price2019/08/27 00:00
Earnings2019/04/30
Annual Earnings2018/10/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.